CASSAVA SCIENCES INC

Clinical-stage biotech developing oral drug simufilam for CNS disorders like TSC-related epilepsy.

SAVA | NDAQ

Overview

Corporate Details

ISIN(s):: US69562K5065 (+1 more)
LEI:
Country:: United States of America
Address:: 6801 N CAPITAL OF TEXAS HIGHWAY, 78731 AUSTIN
Website:: https://www.cassavasciences.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing novel treatments for Central Nervous System (CNS) disorders. The company's lead drug candidate is simufilam, a proprietary, investigational oral small molecule designed to modulate the activity of the filamin A (FLNA) protein, a key regulator in neuronal development. Cassava's primary development program is advancing simufilam as a potential therapy for tuberous sclerosis complex (TSC)-related epilepsy, supported by preclinical data showing a reduction in seizure activity. The company is also exploring the potential application of simufilam for other CNS indications.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all CASSAVA SCIENCES INC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CASSAVA SCIENCES INC

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for CASSAVA SCIENCES INC via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
CTC BIO, INC. Develops pharmaceuticals and feed additives for human and animal health using fermentation tech.	South Korea	060590
Cue Biopharma, Inc. Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.	United States of America	CUE
Cullinan Therapeutics, Inc. Developing differentiated immune-modulating therapies for cancer and autoimmune diseases.	United States of America	CGEM
CUMBERLAND PHARMACEUTICALS INC Acquires and commercializes branded medicines for acute care, gastroenterology, and oncology.	United States of America	CPIX
Cuorips Inc. Develops iPS cell therapies, like a cardiomyocyte sheet for severe heart failure.	Japan	4894
Cuprina Holdings (Cayman) LTD Biomedical firm specializing in Maggot Debridement Therapy for wound care in Singapore & Hong Kong.	United States of America	CUPR
curacle co., ltd. Developing drugs for intractable diseases like diabetes caused by vascular damage and aging.	South Korea	365270
Curanex Pharmaceuticals Inc Developing botanical drugs for inflammatory diseases, diabetes, and COVID-19.	United States of America	CURX
Curevac Pioneering mRNA technology to create vaccines and therapies for infectious diseases, cancer, and more.	Germany	CVAC
CureVac N.V. Pioneering mRNA technology for prophylactic vaccines and novel cancer immunotherapies.	United States of America	CVAC